James Trimm, MD
Interventional Cardiology · Birmingham, ALNPI 1487790481
Payments from drug & device makers
Across 278 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Silk Road Medical, Inc.$910
- Novartis$662
- Pfizer$584
- Boehringer Ingelheim$452
- Boston Scientific$385
- E.r. Squibb & Sons, L.L.C.$371
- plus $3K from 29 others
What the payments were for
- Travel & lodging$5509%
- Food & beverage$5,89891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Silk Road Medical, Inc. | 8 | $910 |
| Novartis | 49 | $662 |
| Pfizer | 29 | $584 |
| Boehringer Ingelheim | 28 | $452 |
| Boston Scientific | 10 | $385 |
| E.r. Squibb & Sons, L.L.C. | 19 | $371 |
| Sanofi-aventis U.S. LLC | 19 | $299 |
| Medtronic | 9 | $257 |
| Amgen | 17 | $256 |
| Philips North America LLC | 8 | $243 |
| Abbott | 4 | $225 |
| Johnson & Johnson | 13 | $191 |
| AstraZeneca | 11 | $161 |
| Shockwave Medical, Inc | 1 | $157 |
| Arbor Pharmaceuticals, Inc. | 2 | $147 |
| Merck | 8 | $138 |
| Bayer | 7 | $132 |
| Cook Medical LLC | 1 | $122 |
| Edwards Lifesciences | 3 | $118 |
| Angiodynamics, Inc. | 2 | $84 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $81 |
| Lundbeck LLC | 3 | $65 |
| Alnylam Pharmaceuticals Inc. | 3 | $52 |
| Reflow Medical Inc | 3 | $47 |
| Cardiovascular Systems Inc. | 3 | $43 |
| Amarin Pharma, Inc. | 3 | $39 |
| Biosense Webster, Inc. | 1 | $38 |
| Bridgebio Pharma, Inc. | 2 | $37 |
| Endologix LLC | 1 | $36 |
| Penumbra, Inc. | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $23 |
| Novo Nordisk | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Veryan Medical Incorporated | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENROUTE Transcarotid Neuroprotection System$995
- ENROUTE Transcarotid Stent$834
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$161
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$157
- WATCHMAN Access System$148
- Mitra Clip system$143
- Edarbi$139
- Zilver PTX$122
- ELIQUIS$121
- ONYX FRONTIER$119
- Stellarex$103
How this compares
$6,448 in reported general payments places this provider in the 35th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 579 | $454,610 |
| CamzyosMavacamten | 46 | $385,087 |
| Repatha SureclickEvolocumab | 198 | $128,814 |
| XareltoRivaroxaban | 64 | $55,159 |
| FarxigaDapagliflozin Propanediol | 83 | $54,716 |
| JardianceEmpagliflozin | 59 | $54,135 |
| BrilintaTicagrelor | 31 | $19,727 |
| Praluent PenAlirocumab | 30 | $15,653 |
| Metoprolol Succinate | 544 | $10,929 |
| Droxidopa | 20 | $9,372 |
| Atorvastatin Calcium | 582 | $8,611 |
| Rosuvastatin Calcium | 399 | $8,339 |
| Ranolazine ErRanolazine | 101 | $8,178 |
| Sildenafil Citrate | 30 | $7,211 |
| JanuviaSitagliptin Phosphate | 13 | $7,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $584 | $454,610579 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $371 | $385,08746 claims |
| AstraZenecaFarxiga, Brilinta | $161 | $74,443114 claims |
| Johnson & JohnsonXarelto | $191 | $55,15964 claims |
| Boehringer IngelheimJardiance | $452 | $54,13559 claims |
| MerckJanuvia | $138 | $7,13613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Birmingham
- Robert FosterBirmingham$553K
- Brigitta BrottBirmingham$376K
- Gary RoubinBirmingham$196K
- Massoud LeesarBirmingham$160K
- David SchultzBirmingham$95K
- Joshua CockrellBirmingham$93K
- Hasan GuvenBirmingham$86K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
- Jacob TownsendBirmingham$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.